drugset
drugset / Trial / NCT04069936

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

NCT04069936 ↗

Phase 2 Terminated 19 enrolled WindMIL Therapeutics Bristol-Myers Squibb · collab
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and efficacy of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC who are refractory or relapsing to a PD-1 containing regimen.

Timeline

Start
2019-10-15
Primary completion
2021-10-28
Completion
2021-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject MILs™ - NSCLC Cell therapy — —
Subject Nivolumab Monoclonal antibody — —
Subject Tadalafil Small molecule — —

Indications

non-small cell lung carcinoma